| 000 | 01604 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515235545.0 | ||
| 264 | 0 | _c20110215 | |
| 008 | 201102s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.25480 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoore, Kathleen N | |
| 245 | 0 | 0 |
_aDoes the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. _h[electronic resource] |
| 260 |
_bCancer _cDec 2010 |
||
| 300 |
_a5407-14 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 |
_aEndometrial Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aTian, Chunqiao | |
| 700 | 1 | _aMcMeekin, D Scott | |
| 700 | 1 | _aThigpen, J Tate | |
| 700 | 1 | _aRandall, Marcus E | |
| 700 | 1 | _aGallion, Holly H | |
| 773 | 0 |
_tCancer _gvol. 116 _gno. 23 _gp. 5407-14 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.25480 _zAvailable from publisher's website |
| 999 |
_c20072670 _d20072670 |
||